Survival in 31 670 patients with thin melanomas: a Swedish population-based study.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
accepted:
02
03
2020
pubmed:
7
3
2020
medline:
15
5
2021
entrez:
6
3
2020
Statut:
ppublish
Résumé
The incidence of cutaneous malignant melanoma (CMM) continues to increase in most countries worldwide and the majority are diagnosed with thin tumours (≤ 1 mm). The aim of the present study was to investigate the melanoma-specific survival (MSS) as well as conditional MSS (CMSS) in patients with thin CMM in Sweden. Clinical and histological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with thin CMM between 1990 and 2017. Patients were followed until the end of 2017. MSS as well as CMSS for different thickness groups were calculated using the Kaplan-Meier method and Cox regression analyses were used to calculate for survival differences between thickness groups. There were 31 670 patients included for final analyses. The overall 10- and 20-year MSS for thin CMMs was 97% [95% confidence interval (CI) 97-97] and 95% (95% CI 95-96), respectively. From 0·7 mm and above, MSS decreased significantly with increasing thickness level. All thickness groups had an increased survival over time. The lowest CMSS was confirmed for men with 1·0 mm in thickness but their 10-year CMSS increased steadily over time. Women had overall better MSS as well as CMSS than men. However, the relation between MSS and CMSS was similar for both sexes. MSS was confirmed as excellent for patients with thin CMMs in Sweden. Although we could show a decreased MSS for patients with 0·7 mm thickness and above, the long-term survival and, in addition, a very favourable CMSS for those patients do not support more extended follow-up programmes than the current recommendations in Sweden.
Sections du résumé
BACKGROUND
The incidence of cutaneous malignant melanoma (CMM) continues to increase in most countries worldwide and the majority are diagnosed with thin tumours (≤ 1 mm).
OBJECTIVES
The aim of the present study was to investigate the melanoma-specific survival (MSS) as well as conditional MSS (CMSS) in patients with thin CMM in Sweden.
PATIENTS AND METHODS
Clinical and histological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with thin CMM between 1990 and 2017. Patients were followed until the end of 2017. MSS as well as CMSS for different thickness groups were calculated using the Kaplan-Meier method and Cox regression analyses were used to calculate for survival differences between thickness groups.
RESULTS
There were 31 670 patients included for final analyses. The overall 10- and 20-year MSS for thin CMMs was 97% [95% confidence interval (CI) 97-97] and 95% (95% CI 95-96), respectively. From 0·7 mm and above, MSS decreased significantly with increasing thickness level. All thickness groups had an increased survival over time. The lowest CMSS was confirmed for men with 1·0 mm in thickness but their 10-year CMSS increased steadily over time. Women had overall better MSS as well as CMSS than men. However, the relation between MSS and CMSS was similar for both sexes.
CONCLUSIONS
MSS was confirmed as excellent for patients with thin CMMs in Sweden. Although we could show a decreased MSS for patients with 0·7 mm thickness and above, the long-term survival and, in addition, a very favourable CMSS for those patients do not support more extended follow-up programmes than the current recommendations in Sweden.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-67Subventions
Organisme : S. Paulsson Fund
Organisme : M. Paulsson Fund
Organisme : LMK Foundation
Organisme : Welander Finsen Foundation
Organisme : Gorthon Foundation
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136:1161-71.
Erdmann F, Lortet-Tieulent J, Schuz J et al. International trends in the incidence of malignant melanoma 1953-2008 - are recent generations at higher or lower risk? Int J Cancer 2013; 132:385-400.
Karimkhani C, Green AC, Nijsten T et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol 2017; 177:134-40.
Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206.
Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-8.
Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75:2484-91.
Måsbäck A, Olsson H, Westerdahl J et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11:435-45.
Murali R, Haydu LE, Long GV et al. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Ann Surg Oncol 2012; 19:1782-9.
Lyth J, Hansson J, Ingvar C et al. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. Br J Dermatol 2013; 168:779-86.
McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003; 98:1223-31.
Gershenwald JE, Scolyer RA, Hess KR et al.; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472-92.
Green AC, Baade P, Coory M et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30:1462-7.
Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol 2018; 25:894-902.
Amin MB, Edge S, Greene F et al., eds. AJCC Cancer Staging Manual, 8th edn. New York: Springer International Publishing, 2017.
Hieke S, Kleber M, Konig C et al. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res 2015; 21:1530-6.
Haydu LE, Scolyer RA, Lo S et al. Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis. J Clin Oncol 2017; 35:1721-9.
Lyth J. Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study. Melanoma Res 2018; 28:637-40.
Merrill RM, Bateman S. Conditional melanoma cancer survival in the United States. Cancers 2016; 8:20.
van der Leest RJ, van Steenbergen LN, Hollestein LM et al. Conditional survival of malignant melanoma in the Netherlands: 1994-2008. Eur J Cancer 2014; 50:602-10.
Vecchiato A, Zonta E, Campana L et al. Long-term survival of patients with invasive ultra-thin cutaneous melanoma: a single-center retrospective analysis. Medicine 2016; 95:e2452.
Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol 2015; 172:885-915.
Idorn LW, Wulf HC. Socioeconomic status and cutaneous malignant melanoma in Northern Europe. Br J Dermatol 2014; 170:787-93.
Johnson-Obaseki SE, Labajian V, Corsten MJ, McDonald JT. Incidence of cutaneous malignant melanoma by socioeconomic status in Canada: 1992-2006. J Otolaryngol Head Neck Surg 2015; 44:53.
Brooke HL, Talback M, Hornblad J et al. The Swedish cause of death register. Eur J Epidemiol 2017; 32:765-73.
Elmore JG, Barnhill RL, Elder DE et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017; 357:j2813.
Monshi B, Vujic M, Kivaranovic D et al. The burden of malignant melanoma - lessons to be learned from Austria. Eur J Cancer 2016; 56:45-53.
van der Leest RJ, Zoutendijk J, Nijsten T et al. Increasing time trends of thin melanomas in the Netherlands: what are the explanations of recent accelerations? Eur J Cancer 2015; 51:2833-41.
Maurichi A, Miceli R, Camerini T et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol 2014; 32:2479-85.
Nationella vårdprogrammet för hudmelanom. https://www.cancercentrum.se/samverkan/cancerdiagnoser/hud-och-ogon/vardprogram/gallande-vardprogram/. 2019 (accessed 5 May 2019).
Maroti M, Ulff E, Lyth J, Falkmer U. A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence. Eur J Dermatol 2016; 26:586-91.
Lyth J, Falk M, Maroti M et al. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register. J Eur Acad Dermatol Venereol 2017; 31:1468-74.